Finch Therapeutics
200 Inner Belt Road
Suite 400
Somerville
Massachusetts
02143
United States
Website: http://finchtherapeutics.com
Email: info@finchtherapeutics.com
About Finch Therapeutics
Finch Therapeutics is a mission-driven biopharmaceutical company that aims to develop novel microbial therapies serving patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful experiences with fecal transplantation. Through this and other clinical datasets, Finch identifies the microbes that drive desirable clinical outcomes, and develops therapies that deliver those microbial communities to patients. FIN-403 is both Finch’s lead clinical program and a valuable tool for its broader human-first discovery strategy.YEAR FOUNDED:
2014
LEADERSHIP:
CEO: Mark Smith
COO: Andrew Noh
CFO: Susan Clancy
JOBS:
Please click here for Finch job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
63 articles with Finch Therapeutics
-
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
1/24/2023
Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets.
-
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
11/10/2022
Finch Therapeutics Group, Inc. provided corporate updates and reported financial results for the third quarter ended September 30, 2022.
-
Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
11/9/2022
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that the company will present at the following investor conferences.
-
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
10/24/2022
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the presentation of biomarker data from PRISM-EXT, a Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI), at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.
-
Finch announced that it is slashing its headcount by around 37% and suspending its planned Phase I study in autism a week after Takeda withdrew from its multi-year collaboration.
-
Finch Therapeutics Provides Business Update - Sep 01, 2022
9/1/2022
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced plans to reduce its workforce by approximately 37% as part of an ongoing strategic review of its business and portfolio.
-
Following the termination of a multi-year collaboration with Takeda, Finch has regained the rights to two assets, FIN-524 and FIN-525, assessed for forms of inflammatory bowel disease.
-
Finch Therapeutics to Participate in Upcoming June 2022 Investor Conferences
6/2/2022
Finch Therapeutics Group, Inc. announced that Mark Smith, PhD, Chief Executive Officer, will participate in fireside chats at the following investor conferences.
-
Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
5/17/2022
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.
-
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
5/16/2022
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.
-
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
5/9/2022
Finch Therapeutics Group, Inc. today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights.
-
ImmunoGen, which is developing Antibody-drug conjugates (ADCs) for the treatment of cancer, is on a hiring spree. The company is looking to hire for more than 200 positions by the end of 2022.
-
A roundup of last week's top clinical trial updates and news.
-
Finch Therapeutics has been given the green light to continue the Phase III Prism4 clinical trial, investigating the efficacy of CP101 in fighting recurrent C. difficile infections (CDI).
-
Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND
4/28/2022
Finch Therapeutics Group, Inc. announced that the U.S. Food and Drug Administration has removed the clinical hold on Finch’s investigational new drug application for CP101.
-
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs
4/19/2022
Finch Therapeutics Group, Inc. today announced plans to reduce its workforce by approximately 20%.
-
Finch Therapeutics has slashed its headcount by 20% in order to free funds to focus its resources on its programs in recurrent C. difficile infection and autism spectrum disorder
-
Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
3/31/2022
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, reported fourth quarter and full year 2021 financial results and provided business updates.
-
The FDA asked Finch to pause enrollment for the trial on CP101 in recurrent C. difficile infection, pending details on how SARS-CoV-2 donor samples will be shipped to the vendor.
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.